Development and validation of a diagnostic instrument to detect platelet activation levels from whole blood samples.

开发和验证用于检测全血样本中血小板活化水平的诊断仪器。

• 批准号: 355118-2007
• 负责人: Vermette, Patrick
• 金额: $ 7.26万
• 依托单位: Université de Sherbrooke
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2007
• 资助国家: 加拿大
• 起止时间: 2007-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=365962
• 关键词: Development; validation; diagnostic; instrument; detect

This project involves the development and validation of Technology that can be used as medical diagnostic tools to quantify platelet activation in individual at-risk, or being treated for cardiovascular events. The products contemplated will allow clinicians to assess the effectiveness of anti-platelet therapies and patients to monitor frequently and without professional assistance their level of platelet activation, which is an indicator o the likelihood of suffering a cardiovascular injury such as a stroke.The medical diagnostic market is a very large market that is dominated by high-capitalisation companies. Despite this and the presence of regulations in this market, it is open to novel technologies and to companies commercialising them through patents or know-how.The cardiovascular sector occupies a large portion of the health-related costs in North America. In this part of the world, 29% of all deaths are due to cardiovascular diseases. More than 80% of Canadians are considered at risk for cardiovascular diseases. These diseases are the leading cause of invalidity in North America. Although platelet activation is known to be an important indicator of cardiovascular events and an important indicator of treatment efficiency, no routine tests are available to accurately measure it in the clinic or at home. A test such as that offered by our Technology could easily create a market as large as that existing for portable glucose sensors, for example, as more than three times more individuals suffer from cardiovascular diseases than from diabetes. The market for portable glucose sensors is expected to exceed 9 billion dollars US in sales within the next five years.

该项目涉及技术的开发和验证，该技术可用作医疗诊断工具，以量化处于风险中或正在接受心血管事件治疗的个体的血小板活化。预期的产品将允许临床医生评估抗血小板治疗的有效性，并允许患者在没有专业人员帮助的情况下频繁监测其血小板活化水平，这是遭受心血管损伤（如中风）的可能性的指标。医疗诊断市场是一个由高资本公司主导的非常大的市场。尽管存在这些问题，而且该市场存在监管规定，但它对新技术以及通过专利或专有技术将其商业化的公司开放。心血管领域占据了北美健康相关成本的很大一部分。在世界的这一地区，29%的死亡是由于心血管疾病。超过80%的加拿大人被认为有患心血管疾病的风险。这些疾病是北美残疾的主要原因。虽然血小板活化是心血管事件的重要指标，也是治疗效果的重要指标，但目前还没有常规检测方法可以在诊所或家中准确测量。例如，我们的技术提供的测试可以很容易地创造一个与便携式葡萄糖传感器现有市场一样大的市场，因为患有心血管疾病的人数是糖尿病的三倍多。便携式葡萄糖传感器的市场预计将在未来五年内超过90亿美元的销售额。